STAT+: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and more
An FDA advisory panel recommended use of an experimental Replimune treatment for advanced melanoma that the agency has rejected twice
<p>An FDA advisory panel recommended use of an experimental Replimune treatment for advanced melanoma that the agency has rejected twice</p>